Rekvina Laboratories Limited Conducts Extra

Rekvina Laboratories Limited successfully conducted its 1st/2026-27 Extra-Ordinary General Meeting (EGM) on Friday, April 10, 2026, at 11:30 A.M. The meeting was held at the company's registered office located at 36, Sampatrao Colony, Next to Royal Hotel, Alkapuri, Vadodara, Gujarat, in compliance with the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting Attendance and Leadership

The EGM was chaired by Mr. Amit Mukesh Shah, Chairman & Managing Director, with a total of 17 members present in person. The board representation included Mr. Prateek Satishkumar Jain (Non-Executive Independent Director) and Mr. Surbhit Shah (Executive Director & Chief Financial Officer). Mr. Deepak Khandelwal served as Company Secretary & Compliance Officer, while Mr. Suhas Bhattbhatt was appointed as Scrutinizer to oversee the voting process.

Role Name Chairman & Managing Director Mr. Amit Mukesh Shah Non-Executive Independent Director Mr. Prateek Satishkumar Jain Executive Director & CFO Mr. Surbhit Shah Company Secretary Mr. Deepak Khandelwal Scrutinizer Mr. Suhas Bhattbhatt Members Present 17

Key Resolutions for Approval

The EGM addressed six critical resolutions that were put before the members for approval:

Increase in Authorised Share Capital and Alteration of Capital Clause of the Memorandum of Association

Alteration of Articles of Association of the Company

Investments, Loans, Guarantees and Security in excess of limits specified under section 186 of Companies Act, 2013

Approval of Related Party Transactions proposed to be entered into by the Company

Issuance and Allotment of Equity Shares by way of preferential issue on private placement basis for consideration other than cash

Issuance and Allotment of Equity Shares by way of preferential issue on private placement basis for cash consideration to non-promoter category

Member Engagement and Clarifications

During the proceedings, members actively sought clarifications regarding the proposed fund-raising initiatives and the company's future course of action. Mr. Amit Mukesh Shah, Managing Director, provided comprehensive explanations and insights to address member queries to their satisfaction. The interactive session demonstrated member engagement in the company's strategic direction and capital restructuring plans.

Voting Process and Conclusion

The voting process was conducted through polling papers under the supervision of the appointed Scrutinizer, ensuring transparency and fairness in the decision-making process. After addressing all member queries and completing the voting procedures, the meeting concluded at 11:50 A.M. with a vote of thanks to the Chair.

The EGM represents a significant step in Rekvina Laboratories Limited's corporate governance and strategic planning, with the resolutions focusing on capital enhancement and operational flexibility through various fund-raising mechanisms.

Rekvina Laboratories Limited has officially notified BSE Limited that it is claiming exemption from submitting the Annual Secretarial Compliance Report for the financial year ended 31st March, 2026. The communication, dated 06.04.2026, was addressed to the Department of Corporate Services at BSE.

Regulatory Exemption Details

The company has invoked Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which provides specific exemptions for smaller listed entities. Under this regulation, companies meeting certain financial criteria are exempt from various corporate governance provisions.

Exemption Parameter: Threshold Limit Paid-up Equity Share Capital: Not exceeding Rs 10 crores Net Worth: Not exceeding Rs 25 crores Assessment Period: Last day of previous financial year

Scope of Exemptions

The exemption covers extensive corporate governance provisions under SEBI regulations. The company is relieved from compliance with multiple regulations and specific clauses that typically apply to larger listed entities.

Exempt Regulations:

Regulations 17, 17A, 18, 19, 20, 21, 22, 23, 24, 24A, 25, 26, 26A, 27

Clauses (b) to (i) and (t) of sub-regulation (2) of regulation 46

Para C, D and E of Schedule V

Company Information

Rekvina Laboratories Limited operates under CIN L24231GJ1988PLC01145 with its registered office located at 36, Sampatrao Colony, Next to Royal Hotel, Alkapuri, Baroda. The notification was signed by Director Surbhit Mukesh Shah (DIN: 01993300), confirming the company's position regarding the non-applicability of the Annual Secretarial Compliance Report requirement.

The company has requested BSE to acknowledge this exemption claim and take note of its regulatory status for the financial year 2026.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.